Jean-Luc Lemercier
Director/Board Member bei CARMAT
Vermögen: 17 Mio $ am 31.03.2024
Profil
Mr. Jean-Luc Lemercier is a Corporate Vice President-EMEA at Edwards Lifesciences Corp.
and an Independent Director at Carmat SA. He is on the Board of Directors at Carmat SA. Mr. Lemercier was previously employed as a Vice President-EMEA Region by Edwards Lifesciences (Canada), Inc. He received his undergraduate degree from Université Claude Bernard Lyon 1.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.04.2024 | 173 849 ( 0,03% ) | 17 Mio $ | 31.03.2024 |
Aktive Positionen von Jean-Luc Lemercier
| Unternehmen | Position | Beginn |
|---|---|---|
| CARMAT | Director/Board Member | 02.01.2017 |
| EDWARDS LIFESCIENCES CORPORATION | Corporate Officer/Principal | 01.07.2017 |
Ehemalige bekannte Positionen von Jean-Luc Lemercier
| Unternehmen | Position | Ende |
|---|---|---|
Edwards Lifesciences (Canada), Inc.
 Edwards Lifesciences (Canada), Inc. Pharmaceuticals: MajorHealth Technology Part of Edwards Lifesciences Corp., Edwards Lifesciences (Canada), Inc. develops, manufactures and supplies products to treat cardiovascular diseases. The private company is based in Mississauga, Canada. | Corporate Officer/Principal | - |
Ausbildung von Jean-Luc Lemercier
| Université Claude Bernard Lyon 1 | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| EDWARDS LIFESCIENCES CORPORATION | Health Technology |
| CARMAT | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Edwards Lifesciences (Canada), Inc.
Edwards Lifesciences (Canada), Inc. Pharmaceuticals: MajorHealth Technology Part of Edwards Lifesciences Corp., Edwards Lifesciences (Canada), Inc. develops, manufactures and supplies products to treat cardiovascular diseases. The private company is based in Mississauga, Canada. | Health Technology |
